Powered by
PLYMOUTH—Esperovax, the Plymouth developer of oral mRNA biologics, and Boston-based Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a partnership to …
ANN ARBOR—Evoq Therapeutics Inc., the Ann Arbor-based immune disease drug development firm, and Foster City, Calif.-based Gilead Sciences Inc. (Nasdaq: GILD) have announced a collaboration and licensing agreement to advance …
PLYMOUTH—Esperovax, a Plymouth-based developer of oral vaccines, announced a new, exclusive licensing agreement with Innovation Partners at the University of Michigan to produce vaccines and therapeutics using a novel yeast-based …
ANN ARBOR–CareEvolution has announced a membership with the Decentralized Trials & Research Alliance (DTRA) to collaborate in the efforts to improve global adoption and education surrounding decentralized research, participant-centric trial …
WIXOM–Rockwell Medical Inc. (Nasdaq: RMTI), the Wixom-based developer of products for patients suffering from blood and kidney disorders, announced it would suspend develop of new pharmaceutical products, and concentrate instead …
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR) has sold 32,142,858 additional shares of its common stock to the public for $225 million, before deducting underwriting discounts, commissions, and other offering expenses. …
CANTON TWP.—MMS Holdings, the contract research organization for the pharmaceutical industry, announced the hiring of Kevin Chartier as principal advisor of biostatistics and submissions planning.Chartier will work with the biostatistics …
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR), developers of a new class of cholesterol-lowering drugs, announced a 40 percent work force reduction and said it would focus its marketing efforts more …
ANN ARBOR—BlueWillow Biologics Inc., a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, announced positive interim results from the Phase 1 clinical trial of BW-1010, its next-generation intranasal anthrax vaccine …
CANTON TWP.—Officials at MMS Holdings Inc., a contract research organization for the pharmaceutical industry, announced a pro-bono support program to advance research for ultra-rare diseases. Within this program, MMS will …